Investigational drug · Phase 2
AGMB-129
Also called: Ontunisertib
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Fibrostenotic Crohn's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
6
Any phase or sponsor naming "AGMB-129"
First trial start
2023
Aug 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AGMB-129", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fibrostenotic Crohn's Disease
Approved drugs for the same conditions: Crohn's disease · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "AGMB-129" as an intervention, largest first.
- NOV-ERA - A Clinical Trial to Assess the Efficacy and Safety of Ontunisertib Compared to Placebo in Patients With Fibrostenosing Crohn's DiseasePivotal-lookingRecruiting
Agomab Spain S.L.U.Industry
NCT07683325 · 320 participants (planned) · Start Oct 30, 2026 · Primary completion Dec 31, 2028
Drug: Ontunisertib; Ontunisertib and 2 more · For: Fibrostenotic Crohn's Disease
Sites: Sun City, Arizona; Bradenton, Florida; Albany, New York · 11 sites in all
- STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's DiseasePivotal-lookingCompleted
Agomab Spain S.L.U.Industry
NCT05843578 · 103 participants · Start Aug 1, 2023 · Primary completion Jun 20, 2026
Drug: AGMB-129; Placebo · For: Fibrostenotic Crohn's Disease
Sites: Hamden, Connecticut; Miami, Florida; Orlando, Florida · 52 sites in all
Agomab Spain S.L.U.Industry
NCT07118878 · 30 participants · Start Aug 6, 2025 · Primary completion Sep 15, 2025
Drug: AGMB-129 · For: Fibrostenotic Crohn's Disease
Sites: Edegem, Belgium
Agomab Spain S.L.Industry
NCT06397508 · 25 participants · Start Apr 2, 2024 · Primary completion May 8, 2024
Drug: AGMB-129 · For: Healthy Volunteers
Sites: Edegem, Belgium
Agomab Spain S.L.Industry
NCT05937386 · 14 participants · Start Aug 9, 2023 · Primary completion Sep 6, 2023
Drug: AGMB-129; MDZ · For: Healthy Volunteers
Sites: Edegem, Belgium
Agomab Spain S.L.U.Industry
NCT07672574 · 8 participants (planned) · Start Sep 9, 2026 · Primary completion Jan 31, 2027
Drug: Ontunisertib; [14C]ontunisertib and 1 more · For: Fibrostenotic Crohn's Disease
Sites: Nottingham, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Anti-fibrotic therapy in Crohn's disease: hype or reality-can intestinal fibrosis be targeted effectively?
Honap S, Dignass A, Jairath V, et al. · Expert Rev Gastroenterol Hepatol 2026
- [Intestinal fibrosis in Crohn's disease : towards new therapeutic options?].
Vieujean S, Bequet É, Stepniak M, et al. · Rev Med Liege 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.